Mergers & AcquisitionsMedium•11 November 2026•
1 min read
Samsung Biologics Secures Capital Increase for PolyPeptide Acquisition
Key Facts
1Samsung Biologics announced a 96.8% subscription rate for its 2.7 trillion KRW rights offering.
2Proceeds from the capital increase are designated for the acquisition of PolyPeptide Group AG.
Samsung Biologics announced a 96.8% subscription rate for its 2.7 trillion KRW rights offering. Benzinga reported that the proceeds from this capital increase are designated to fund the acquisition of PolyPeptide Group AG.
The successful completion of the offering secures the necessary funding for the acquisition of the Swiss-based group, indicating investor support for the company's strategic expansion. Market attention remains on the company's ability to clear primary financial hurdles for the merger.